Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Scope

The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)

Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix

Forecasts are presented in pipeline forecast figures & detailed tables

‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided

Key Highlights

AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD

Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US

Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population

Reasons to Buy

Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher

Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market

Reviews ongoing lifecycle management strategies for existing players in the market

A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts

Key Players

AbbVie
Aclaris
Akaal Pharma
Allergan
Amgen
Amorepacific Corporation
AnaptysBio
AntibioTx
AOBiome
Asana BioSciences
AstraZeneca
BioMimetix
Brickell Biotech
Celgene
Chugai
Connect Biopharma
Creabilis
Cutanea Life Sciences
Dermata Therapeutics
Dermavant Sciences
Dermira
DS Biopharma
Eli Lilly
Fountain Biopharma
Galapagos
Galderma
Galectin Therapeutics
Glenmark Pharma
GSK
Haus Bioceuticals
iCo Therapeutics
Immune Pharma
Incyte Corporation
Janssen
Japan Tobacco
Kang Stem Biotech
Kyowa Hakko Kirin
Leo Pharma
Medimetriks
MedImmune
Menlo Therapeutics
MorphoSys
NeRRe Therapeutics
Novan
Novartis
Otsuka
Pfizer
PurGenesis Technologies
Qurient
Ralexar Therapeutics
Realm Therapeutics
Regeneron
Roche
Roivant Sciences
Saniona
Sanofi
Shaperon
Sienna Biopharma
Sterna Biologicals
Therapeutics
Tioga
Valeant
Vanda Pharma
XBiotech
Xencor
Ziarco Pharma

Table of Contents

• Introduction to Sociable Pharma’s ‘Competitor Landscape’

• Executive Summary (Go to Section)

– Key Events & Landscape Updates

• Landscape Updates (Go to Section)

– Order of Entry

– Lifecycle Development

• Pipeline Landscape (Go to Section)

– Pipeline Summary

• Approved Product Development Landscape (Go to Section)

– Lifecycle Development

• Appendix (Go to Section)

– Early Stage Pipeline ‘Watch List’

– Assumptions, Glossary & Abbreviations, and Notes

– Contact Details

$6,400

Can be used by individual purchaser only

$19,200

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.